← Faculty
Publications
- Petry, Neil. “Licensing and regulatory control: radioactivity and radioactive materials.” Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, American Pharmacists Association (APhA), 2020.
- Petry, Neil. “Licensing and regulatory control: radiopharmaceutical oversight.” Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, American Pharmacists Association (APhA), 2020.
- Kane, Ari, et al. “Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG.” J Nucl Med, vol. 59, no. 11, Nov. 2018, pp. 1708–13. Pubmed, doi:10.2967/jnumed.117.202150.
- Nandedkar, Sanjeev D., et al. “Reply.” Muscle Nerve, vol. 58, no. 4, Oct. 2018, pp. E31–32. Pubmed, doi:10.1002/mus.26198.
- Kraus, V. B., et al. “Direct in vivo evidence of activated macrophages in human osteoarthritis.” Osteoarthritis Cartilage, vol. 24, no. 9, 2016, pp. 1613–21. Pubmed, doi:10.1016/j.joca.2016.04.010.
- Bao, Xuhui, et al. “Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.” Invest New Drugs, vol. 34, no. 2, Apr. 2016, pp. 149–58. Pubmed, doi:10.1007/s10637-015-0318-3.
- Chin, Bennett B., et al. “Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane.” J Nucl Med, vol. 55, no. 5, May 2014, pp. 765–71. Pubmed, doi:10.2967/jnumed.113.124057.
- Barrett, John A., et al. “First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 54, no. 3, Mar. 2013, pp. 380–87. Epmc, doi:10.2967/jnumed.112.111203.